Company insight
Shaping the future of home drug delivery
Greg Moakes, EVP, new business development for the Device Technology unit at LTS, discusses the rapid growth of the on-body drug delivery system market and the patient benefi ts driving demand. The company details how its customisable platform gives pharma partners greater fl exibility, faster time to market, and scalable solutions. With the successful launch of UDENYCA ONBODY™, the company is poised to lead the future of innovative drug delivery technologies.
Let’s start with some market dynamics – what is the current state of play with OBDS and what are your expectations for the future? Rather like autoinjectors in the past, so much has spoken about the concept of a configurable on-body drug delivery system (OBDS) that some industry professionals may be thinking the prospects of this technology becoming reality is more hyperbole than high probability. As market data verifies, however, this is simply not the case. The OBDS market is witnessing exponential growth, driven by the clear patient benefits of convenience, precision and ease of use. All designed to support the sector-wide determination to empower patients in managing their treatments at home. In 2023, the market generated US$ 390.7 million in revenue, with projections soaring to US$ 796.1 million by 2034, growing at a 6.8% CAGR.
It is therefore the absolute conviction of our device team at LTS that the demand for configurable, multi-volume OBDS platforms will continue to grow at an exciting rate – a belief borne out by market data and the recent success of the UDENYCA ONBODY™ device.
You offer an entirely customisable platform – what benefits does this bring pharma partners? Our configurable platform provides the flexibility to support wide variations in dose volume and dosing regimen, allowing pharma partners to tailor their devices according to patient need. One example is the point-of-care loaded configuration, where volumes up to 2mL are prepared within the device by a healthcare professional. This iteration is
Greg Moakes, EVP,new business development for the Device Technology unit, LTS
compatible with both standard vials (6R, 8R, 15R, 20R and 25R) and, via minor adjustments to the outer casing of the device, proprietary cartridges (5ml, 10ml, 15ml and 20ml). Drug loading is simplified by the inclusion of a disinfection chamber with an integrated UV-C LED, which prepares the primary container’s septum prior to engagement with the device’s fluid path.
In all configurations, our devices are built from a platform that shares the same core technology: a software- controlled electromechanical pumping system that can be programmed with the designated infusion profile. This provides significant time-to-market benefits, since device development efforts are almost exclusively focused on software engineering and drug validation.
For both originators and biosimilar organisations, this single platform enables them to deliver a range of their drug products in multiple dose ranges, delivering demonstrable economies of scale, mitigating development times and irradicating many of the traditional risks associated with developing a combination product.
Where are you in the development lifecycle of the platform? The UDENYCA ONBODY device was launched in the US in February 2024
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
having taken just nine months to go from agreement to clinic. Since its launch it has built significant market share, contributing to total net product sales of $66.1 million for UDENYCA in Q3 2024 – up 30% quarter-on-quarter. Throughout this period, demand on our manufacturing facilities has intensified, but LTS has ensured this has been satisfied through effective planning and agile optimisation of the manufacturing capabilities dedicated to the OBI configuration of Sorrel™. There is also a larger configuration, currently in clinic with multiple pharmaceutical partners, which can be pre-filled and pre-loaded to accommodate between 5mL and 50mL.
What benefits does being part of the LTS Group bring?
The advantages are considerable and wide ranging. Firstly, LTS has a world- class reputation built over decades, for delivering painless drug delivery systems for a range of therapies. With sites in the US, Europe and Israel, the business has a global manufacturing footprint that includes final assembly and fill/ finish. And with deep expertise and experience in R&D and commercial functions, LTS continues to lead the way in developing innovative solutions for today’s drug delivery challenges, particularly in the home environment.
What would your message be right now to anyone interested in OBDS as a delivery route? We are ready when you are! ● References available on request
www.ltslohmann.com 21
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
